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The Parasitic Helminth Product ES-62 Suppresses
Pathogenesis in Collagen-Induced Arthritis by Targeting the
Interleukin-17–Producing Cellular Network at Multiple Sites
Miguel A. Pineda,1 Mairi A. McGrath,1 Pauline C. Smith,1 Lamyaa Al-Riyami,2
Justyna Rzepecka,2 J. Alastair Gracie,1 William Harnett,2 and Margaret M. Harnett1
Objective. Among many survival strategies, para-
sitic worms secrete molecules that modulate host im-
mune responses. One such product, ES-62, is protective
against collagen-induced arthritis (CIA), a model of
rheumatoid arthritis (RA). Since interleukin-17 (IL-17)
has been reported to play a pathogenic role in the
development of RA, this study was undertaken to inves-
tigate whether targeting of IL-17 may explain the pro-
tection against CIA afforded by ES-62.
Methods. DBA/1 mice progressively display ar-
thritis following immunization with type II collagen.
The protective effects of ES-62 were assessed by deter-
mination of cytokine levels, flow cytometric analysis of
relevant cell populations, and in situ analysis of joint
inflammation in mice with CIA.
Results. ES-62 was found to down-regulate IL-17
responses in mice with CIA. First, it acted to inhibit
priming and polarization of IL-17 responses by target-
ing a complex IL-17–producing network, involving sig-
naling between dendritic cells and / or CD4 T cells.
In addition, ES-62 directly targeted Th17 cells by down-
regulating myeloid differentiation factor 88 expression
to suppress responses mediated by IL-1 and Toll-like
receptor ligands. Moreover, ES-62 modulated the mi-
gration of / T cells and this was reflected by direct
suppression of CD44 up-regulation and, as evidenced by
in situ analysis, dramatically reduced levels of IL-17–
producing cells, including lymphocytes, infiltrating the
joint. Finally, there was strong suppression of IL-17
production by cells resident in the joint, such as osteo-
clasts within the bone areas.
Conclusion. Our findings indicate that ES-62
treatment of mice with CIA leads to unique multisite
manipulation of the initiation and effector phases of the
IL-17 inflammatory network. ES-62 could be exploited
in the development of novel therapeutics for RA.
Rheumatoid arthritis (RA) is a chronic auto-
immune inflammatory condition, which, despite recent
advances in cytokine therapy, continues to increase in
incidence in the Western world. However, in areas of the
world where helminth infections are endemic, rates of
autoimmune diseases such as RA remain low, leading
to the hypothesis that certain helminth infections may
protect against the development of autoimmunity (1).
In support of this theory, we have previously shown
that ES-62, a phosphorylcholine-containing glycoprotein
secreted by the filarial nematode Acanthocheilonema
viteae, has broad immunomodulatory activities and can
exert powerful antiinflammatory action in the mouse
collagen-induced arthritis (CIA) model of RA (2,3).
Originally, it was proposed that the ability of
ES-62 to inhibit disease severity in the CIA model
reflected the suppression of tumor necrosis factor 
(TNF) production and associated Th1-mediated in-
flammation (2,3). However, it has become increasingly
clear that Th17, rather than Th1, cells appear to be the
pathogenic drivers of inflammation in many auto-
immune conditions, including CIA and RA (4). Consis-
tent with this, neutralization of IL-17 protects against
disease in mice, while overexpression of IL-17 exacer-
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bates pathology (5). Moreover, Th17 cells may be vital in
promoting the chronic destructive phase of arthritis, due
to their ability to induce the expression of RANKL and
activate osteoclasts, thereby leading to bone resorption
(6), as well as stimulating matrix metalloproteinases,
resulting in cartilage breakdown (7,8). Indeed, previous
studies have shown that IL-17 levels are increased in
serum and synovial fluid samples from patients with RA
compared to those from patients with osteoarthritis or
healthy control subjects (9). In contrast, it has been
proposed that interferon- (IFN) may play a protective
role, since IFNR/ mice are more susceptible to the
development of CIA (10), perhaps reflecting abrogation
of counterregulation of Th17 development by IFN-
producing Th1 cells (11). Moreover, IFN is a potent
antagonist of osteoclastogenesis in mice and humans
(12,13) and thus may also act to prevent joint erosion.
Therefore, given these new insights into CIA
pathology, it was important to ascertain the effect, if
any, that ES-62, a molecule being considered in the
context of therapeutic intervention, has on proinflam-
matory IL-17 production, and thus to readdress its
protective role, but in the perspective of IL-17–
associated pathology.
MATERIALS AND METHODS
Induction of CIA in mice. Animals were bred (on a
BALB/c and C57BL/6 background) and/or maintained in the
University of Glasgow Biological Services Units in accordance
with the Home Office UK Licenses PPL60/3580, PPL60/3119,
and PIL60/12183 and the Ethics Review Board of the Univer-
sity of Glasgow. CIA was induced in 8–10-week-old male
DBA/1 mice (Harlan Olac) on day 0 by intradermal immuni-
zation with bovine type II collagen (MD Biosciences) in
Freund’s complete adjuvant (CFA). Mice were treated with
purified endotoxin-free ES-62 (2 g/dose) or phosphate buff-
ered saline (PBS) subcutaneously on days 2, 0, and 21 (2,3),
and cells were recovered from the joints as previously de-
scribed (14).
Ex vivo analysis. Draining lymph node (LN) cells
(106/ml) were incubated with or without 50 ng/ml phorbol
myristate acetate (PMA) plus 500 ng/ml ionomycin for 1 hour,
followed by addition of 10 g/ml brefeldin A (Sigma-Aldrich)
for 5 hours at 37°C with 5% CO2. Phenotypic markers were
labeled using allophycocyanin (APC)–conjugated anti–Toll-
like receptor 4 (anti–TLR-4; R&D Systems), biotinylated
anti-CD44 (BioLegend; detected with phycoerythrin (PE)–
conjugated streptavidin [BD PharMingen]), PerCP-conjugated
anti-CD4 or biotinylated anti-CD4 (detected with Alexa Fluor
450–conjugated streptavidin [BD PharMingen]), or fluorescein
isothiocyanate (FITC)–conjugated anti- (BioLegend) anti-
bodies before the cells were fixed and permeabilized according
to BioLegend protocols. Cells were then labeled using APC-
conjugated anti–IL-17A or PerCP-Cy5.5–conjugated anti–IL-
17A (BioLegend), anti–retinoic acid receptor–related orphan
nuclear receptor t (RORt) (eBioscience; detected with
APC-conjugated anti-rat IgG), and anti–myeloid differentia-
tion factor 88 (anti-MyD88) (Abcam; detected with PE-
conjugated anti-rabbit IgG) antibodies for 30 minutes prior to
flow cytometry, with gating according to appropriate isotype
controls.
Cytokine analysis. Enzyme-linked immunosorbent as-
says (ELISAs) for IL-17A, IL-10 (BioLegend), TNF, IL-6,
IL-23, and IL-27 (eBioscience) were performed according to
the recommendations of the manufacturer. Alternatively, IL-
17A was detected by cytometric bead assay (FlowCytomix).
In vitro cell culture. Bone marrow–derived dendritic
cells (BMDCs) from male DBA/1, C57BL/6, or BALB/c mice
(6–8 weeks old) were derived by in vitro culture in complete
RPMI 1640 medium (containing 2 mM glutamine, 50 units/ml
penicillin, 50 g/ml streptomycin, and 10% fetal calf serum) sup-
plemented with 10% conditioned medium from the granulocyte–
macrophage colony-stimulating factor–transfected X63 my-
eloma cell line and 50 M 2-mercaptoethanol at 37°C in 5%
CO2 for 6 days. Naive CD4CD62L T cells and / T cells
were isolated using Miltenyi magnetic bead technology. For
BMDC–T cell cocultures, BMDCs were incubated with ES-62
(2 g/ml), matured with lipopolysaccharide (LPS) (Salmonella
minnesota; Sigma), and then pulsed with ovalbumin (OVA)
peptide (0–300 nM) before incubation with naive T cells
derived from OVA-specific DO.11.10/BALB/c or OT-II/
C57BL/6 mice for 4 days. For in vitro polarization of Th17
cells, naive LN T cells from BALB/c mice were incubated,
in plates precoated with anti-CD3 (4 g/ml), with anti-CD28
(1.5 g/ml), anti-IFN (5 g/ml), and anti–IL-4 (5 g/ml)
antibodies and recombinant IL-6 (rIL-6) (20 ng/ml), trans-
forming growth factor  (rTGF; 4 ng/ml), and rIL-1 (10 ng/
ml) with or without ES-62 (0–1 g/ml) for 4 days. The / T
cells from BALB/c mice were activated with rIL-1 plus rIL-23
(both at 10 ng/ml) overnight with or without ES-62 (2 g/ml)
before being incubated with BMDCs at different /:DC ratios
(1:2, 1:5, and 1:20). Culture supernatants were collected after
24 hours.
Immunofluorescence analysis. Tissue sections (7 m)
were deparaffinized in xylene and dehydrated in ethanol, and
antigen was retrieved by incubation at 60°C for 2 hours in
10 mM Tris–1 mM EDTA–0.05% Tween 20 buffer (pH 9.0).
Samples were stained with a goat anti-mouse IL-17 antibody
(R&D Systems) or a goat IgG isotype control and DAPI as a
counterstain, at 4°C for 12 hours, followed by staining with a
biotinylated rabbit anti-goat IgG antibody and streptavidin–
Alexa Fluor 647. Images were obtained using an LSM 510
META confocal laser coupled to an Axiovert 200 microscope
(Zeiss) and analyzed with Zeiss LSM Image Browser software.
Laser scanning cytometry. Draining LNs were fixed in
10% formalin at 4°C for 24 hours, transferred to 30% sucrose
in PBS for 48 hours before being frozen in liquid nitrogen
in OCT compound (Bayer), and stored at 70°C. Sections
(7 m) were stained with FITC-conjugated anti-B220 and
PE-conjugated anti–/ T cell receptor (anti–/ TCR) or
isotype controls (BD PharMingen) and mounted in
Vectashield (Vector). Fluorescence was quantified by laser
scanning cytometry (CompuCyte) to generate tissue maps
of the draining LNs using WinCyte software version 3.6
(CompuCyte). Briefly, setting a gate for positive-staining
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B220 B cells generated a tissue map of the localization of
B220 B cells that allowed generation of the indicated gates
designating the paracortical (T cell) and follicular (B220 B
cell) regions that were subsequently copied onto the /
TCR T cell tissue map. This allowed unbiased statistical
quantitation of / TCR T cells within follicular regions by
the WinCyte software following merging of the / TCR T
cell and B220 B cell tissue maps (15).
Quantitative reverse transcriptase–polymerase chain
reaction (RT-PCR). Quantitative RT-PCR and reverse tran-
scription of RNA were performed according to the recommen-
dations of the manufacturer (Applied Biosystems). High-
performance liquid chromatography–purified probes (VH Bio;
Integrated DNA Technologies) contained the reporter 5-6-
carboxyfluorescein (FAM) and quencher TAMRA dyes,
and the sequences were as follows: for RORt, forward
5-CCGCTGAGAGGGCTTCAC-3, reverse 5-TGCAGGA-
GTAGGCCACATTACA-3, and 5-FAM-AAGGGCTTCT-
TCCGCCGCCAGCAG-TAMRA-3. Applied Biosystems as-
say kits for IL-17A, MyD88, and GAPDH (Mm00439618_m,
NM_010851.2, and 4352339E1, respectively) were used. Data
were analyzed using RQ Manager software (Applied Biosys-
tems), and were normalized to the reference reporter
GAPDH.
Statistical analysis. Parametric data were analyzed by
Student’s unpaired 2-tailed t-test or by one-way analysis of
variance followed by the Newman-Keuls post-test. Normalized
data were analyzed by Kruskal-Wallis test, and the Mann-
Whitney test was used for the analysis of clinical CIA scores.
P values less than 0.05 were considered significant.
RESULTS
Association of ES-62 protection against CIA with
down-regulation of IL-17 responses. ES-62 exhibits an-
tiinflammatory action, as evidenced by the significant
reduction in articular score and hind paw swelling
observed in ES-62–treated mice with CIA (Figure 1A).
Disease incidence was also delayed and reduced in these
ES-62–treated mice (Figure 1A). Consistent with the
notion that IL-17 plays a pathogenic role in CIA, we
observed a strong positive correlation of serum levels of
IL-17 (IL-17A) (Figure 1B), but not IFN (data not
shown), with disease scores in animals with CIA. Thus,
to assess whether protection by ES-62 is associated with
Figure 1. ES-62 protects against collagen-induced arthritis (CIA). A, Mean  SEM clinical score (left) and paw width (middle) in mice with CIA
treated with phosphate buffered saline (PBS) (solid squares; n  43 for clinical score and n  9 for paw width) or ES-62 (open squares; n  32 for
clinical score and n  9 for paw width), and disease incidence in mice with CIA treated with PBS (solid line) or ES-62 (broken line) (right). Disease
incidence was defined as the percentage of animals that developed a severity score of 1. B, Serum interleukin-17 (IL-17) levels in mice with CIA.
The left panel shows a significant correlation between serum IL-17 level and clinical score in mice with CIA (number of XY pairs  26; Pearson’s
r  0.6050, P  0.001). The right panel shows serum IL-17 levels in naive mice (n  16), mice with CIA treated with PBS (n  26), and mice with
CIA treated with ES-62 (n  23). Symbols represent the mean of triplicate analyses of individual mice; horizontal lines represent the mean value
for the treatment group. C, Percentages of IL-17 draining lymph node (DLN) cells and joint cells from mice with CIA treated with PBS or ES-62.
The percentage of IL-17 draining LN cells was determined after ex vivo stimulation with phorbol myristate acetate plus ionomycin. Squares
represent individual mice; horizontal lines represent the mean (n  19 PBS-treated mice and 15 ES-62–treated mice for analysis of draining LNs
and n 11 PBS-treated mice and 8 ES-62–treated mice for analysis of joints). D, Retinoic acid receptor–related orphan nuclear receptor t (RORt)
mRNA levels, relative to GAPDH, in mice with CIA treated with PBS (n 4) and mice with CIA treated with ES-62 (n 3). Values are the mean
SEM.   P  0.05;    P  0.01;   P  0.001.
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suppression of IL-17–mediated pathology, the effect of
administration of the helminth product ES-62 on serum
cytokine levels was analyzed. Significantly higher levels
of IL-17 (Figure 1B), but not IFN (data not shown),
were detected in the serum of mice with CIA than in the
serum of naive animals, and exposure to ES-62 in vivo
reduced these to levels similar to those observed in naive
mice.
Consistent with these findings, significant differ-
ences between the PBS-treated mice, but not the ES-62–
treated mice, and naive mice were found in terms of
total numbers of draining LN cells (results not shown),
and significantly higher proportions of draining LN cells
from animals with CIA treated with PBS than from
animals with CIA treated with ES-62 produced IL-17
following ex vivo stimulation with PMA plus ionomycin
(Figure 1C). Moreover, although the differences did not
reach statistical significance, analysis of spontaneous
IL-17 production by cells recovered from the site of
inflammation also showed a reduction in the proportion
of IL-17 cells infiltrating the joint in the ES-62–treated
animals (Figure 1C). Corroboration that ES-62 sup-
pressed Th17 responses was provided by data showing
that RORt messenger RNA (mRNA) levels were sig-
nificantly lower in draining LN cells from the ES-62–
treated mice than in draining LN cells from the PBS-
treated mice (Figure 1D). Targeting of RORt– and
IL-17–associated responses by ES-62 was specific, since
expression of the Th1-associated transcription factor
T-bet was not affected by exposure to the parasite
product (data not shown).
Suppression of the levels of IL-17–producing
CD4 and / T cells by ES-62. CD4 and / T cells
were the 2 major IL-17–producing compartments
(90%) in the draining LNs of mice from all treatment
groups (Figure 2A). Although the mice with CIA
(treated with PBS) tended to have higher numbers of
draining LN CD4 T cells than those from both the
naive and ES-62–treated groups (Figure 2B), there were
no significant differences between any of these groups,
in terms of either proportions or absolute numbers of
CD4 T cells spontaneously producing IL-17 (results
not shown). In contrast, following ex vivo stimulation
with PMA plus ionomycin, while there were no differ-
ences in the proportions of such IL-17 T cells (Figure
2C), significantly higher numbers of CD4 T cells from
the mice with CIA expressed IL-17 relative to the naive
Figure 2. ES-62 targets IL-17–producing CD4 and / T cells. A, Representative plots of the gating patterns of intracellular IL-17 expression by
draining LN cells from mice with CIA treated with PBS or ES-62, showing forward scatter (FSC) on the x-axis versus IL-17 expression on the y-axis
as well as the cellular expression of IL-17 by CD4 cells and / T cell receptors (/ TCR). B, Numbers of CD4 T cells (left) and / T cells (right)
present in the draining LNs of naive mice (n  12), mice with CIA treated with PBS (n  19), and mice with CIA treated with ES-62 (n  15). C
and D, Percentages (C) and absolute numbers (D) of IL-17 CD4 T cells in the draining LNs of naive mice (n  12), mice with CIA treated with
PBS (n  19), and mice with CIA treated with ES-62 (n  15) after stimulation with phorbol myristate acetate plus ionomycin (left panels), and
of / T cells that spontaneously produced IL-17 in the draining LNs of naive mice (n  8), mice with CIA treated with PBS (n  11), and mice
with CIA treated with ES-62 (n  9) (right panels). In B–D, squares represent individual mice; horizontal lines represent the mean.   P  0.05.
See Figure 1 for other definitions.
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group, and this was reduced by exposure to ES-62
(Figure 2D).
Analysis of / T cell responses showed that there
were no significant differences between the groups in
terms of the total numbers of such cells present in the
draining LNs (Figure 2B). However, both the propor-
tions and the absolute numbers of / T cells that
spontaneously produced IL-17 were higher in the mice
with CIA, but not those exposed to ES-62 in vivo, when
compared to those from the naive group (Figures 2C and
D). No differences were detected among the groups,
however, following ex vivo stimulation with PMA plus
ionomycin (data not shown). Interestingly, while unlikely
to be related to its protective effects (given the lack of
correlation between serum IFN levels and disease
score mentioned above and previously reported findings
[10]), we found that ES-62 reduced the percentages of
CD4, /, and CD8 T cells spontaneously produc-
ing IFN (results not shown), which is consistent with
the results of our previous studies showing that ES-62
suppressed IFN recall responses in CIA (2,3).
Attenuation of Th17 responses by both indirect
and direct effects of ES-62. ES-62 modulates DC-
mediated priming and polarization of Th cell responses
in healthy mice (16–18). Thus, we next investigated
whether ES-62 modulated the capacity of DCs to prime
Th17 responses in mice with CIA, by preincubating
BMDCs derived from naive DBA/1 mice with ES-62
before maturing them with LPS in vitro. Although the
LPS-stimulated release of IL-10 was unaffected (data
not shown), we observed that ES-62 significantly inhib-
ited the LPS-induced secretion of the proinflammatory
cytokine TNF and 2 cytokines associated with the
polarization and survival of Th17 cells, IL-6 and IL-23
(Figure 3A). Similarly, BMDCs derived from one group
of DBA/1 mice with CIA (mean  SEM articular score
7.1  0.68) produced reduced levels of TNF, IL-6, and
IL-23 when treated with ES-62 prior to LPS maturation
in vitro (Figure 3B). Moreover, while IL-23 could not
be detected, BMDCs derived from a second group of
DBA/1 mice with CIA (mean  SEM articular score
5.4  1.6) spontaneously produced significantly more
Figure 3. ES-62 down-regulates dendritic cell (DC)–driven Th17 cell priming in vitro. A and B, Levels of tumor necrosis factor  (TNF), IL-6, and
IL-23 in bone marrow–derived DCs (BMDCs) from naive DBA/1 mice (A) and DBA/1 mice with CIA (B). Mouse BMDCs were preincubated with
ES-62 (n  4 naive mice and n  4 mice with CIA) or without ES-62 (RPMI; n  5 naive mice and n  7 mice with CIA) for 24 hours prior to
stimulation with lipopolysaccharide (LPS) for 24 hours, and TNF, IL-6, and IL-23 levels were then analyzed. Values are the mean  SEM of
triplicate samples from individual mice. C, Spontaneous production of IL-6 by BMDCs from naive DBA/1 mice, DBA/1 mice with CIA treated with
PBS, and DBA/1 mice with CIA treated with ES-62. Values are the mean  SEM of triplicate samples from individual mice (n  4 mice per group).
D, IL-17A levels, measured by enzyme-linked immunosorbent assay, in ovalbumin (OVA)–pulsed LPS-matured or immature (RPMI) BMDCs from
C57BL/6 mice. BMDCs had been preincubated with or without ES-62 and cocultured with naive OT-II T cells for 4 days. Values in the left panel
are the mean SD of triplicate samples from a single experiment. Values in the right panel are the mean SEM percent maximum (LPS) response
of pooled results from 5 independent experiments where data were normalized to the LPS response at 300 nM OVA.   P  0.05;    P  0.01;
  P  0.001. See Figure 1 for other definitions.
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IL-6, but not TNF or IL-10, than those derived from
either naive DBA/1 mice (articular score 0) or DBA/1
mice with CIA that had been exposed to ES-62 in vivo
(mean  SEM articular score 1.8  0.5) (Figure 3C and
results not shown). Taken together, these results suggest
that ES-62 suppresses the generation of Th17-polarizing
cytokines by DCs in mice with CIA. Consistent with
these findings, ES-62–treated DCs showed a reduced
ability to skew naive OVA-specific T cells toward a Th17
phenotype (Figure 3D).
We next investigated whether ES-62 also directly
affects Th17 cells. Naive T cells were primed using
anti-CD3 plus anti-CD28 antibodies in the presence of
the cytokines IL-6, TGF, and IL-1 and neutralizing
antibodies specific for IFN and IL-4, to induce in vitro
differentiation of Th17 cells. When cells were coincu-
bated with the parasite product, ES-62 directly down-
regulated IL-17 production in a significant and dose-
dependent manner, and this reduction in IL-17 release
was reflected by reduced IL-17 mRNA levels (Figure
4A). We found that the expression of TLR-4, which is
required for ES-62 action (19), was up-regulated during
in vitro priming and differentiation of Th17 cells, in
parallel with that of MyD88 and RORt (Figure 4B).
From a mechanistic point of view, while ES-62 did
not appear to modulate either the surface or intra-
cellular levels of TLR-4 (data not shown), it did induce
down-regulation of the TLR signal transducer, MyD88
(Figure 4C), and this was reflected at the mRNA level
(Figure 4D).
DCs are necessary for ES-62 targeting of IL-17
production by / T cells. To address whether ES-62
likewise directly modulated IL-17 production by / T
cells, / T cells from naive mice were stimulated to
produce IL-17 in vitro in a TCR-independent manner,
using rIL-1 plus rIL-23 (20). Such “activated,” / T cells
produced large amounts of IL-17, whereas resting /
T cells did not. However, ES-62 did not modulate
this response (Figure 5A). Perhaps consistent with these
findings, TLR-4 expression was not detected, and cul-
ture with LPS did not induce / T cell activation
(results not shown). Nevertheless, we found that ES-62
inhibited / T cell activation, as indicated by its ability
to prevent up-regulation of the cell surface marker
CD44 in vitro (Figure 5A) and in vivo (Figure 5B).
Therefore, we next investigated whether DCs
regulated the production of IL-17 by / T cells. LPS-
matured DCs were cocultured with resting or IL-1/IL-
23–stimulated / cells that had been exposed to ES-62
or left untreated. We found that IL-17 production was
Figure 4. ES-62 directly inhibits Th17 polarization in vitro. A, Levels of IL-17, determined by enzyme-linked immunosorbent assay, in Th17 cells
from BALB/c mice, differentiated in vitro and left untreated or treated with ES-62 (0–1 g/ml). Values in the left panel are the mean  SD of
triplicate samples from a single representative experiment. Values in the middle panel are the mean  SEM of samples pooled from 3 independent
experiments, normalized to the values in control (untreated) Th17 cells. Values in the right panel are the mean SD mRNA expression in triplicate
samples from a single experiment, relative to GAPDH.   P  0.05;   P  0.01;   P  0.001, versus untreated cells. B, Expression of
RORt, surface Toll-like receptor 4 (TLR-4), and myeloid differentiation factor 88 (MyD88) during in vitro Th17 polarization, determined by flow
cytometric analysis. Expression levels relative to isotype control (broken lines) are shown for day 0 (gray areas), day 2 (thin lines), and day 4 (thick
lines). C, Reduction in the expression of MyD88 (black line) in Th17 cells treated with ES-62 (1 g/ml; gray line), as determined by flow cytometric
analysis (left) and geometric mean analysis (mean fluorescence intensity [MFI]; right). Values are the mean  range from 2 independent
experiments. D, MyD88 mRNA expression, relative to GAPDH, in control and ES-62–treated Th17 cells. Values are the mean  range from 2
independent experiments. See Figure 1 for other definitions.
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reduced in such ES-62–treated DC–/ T cell cocultures
(Figure 5C). Furthermore, IL-17 and RORt mRNA
levels were reduced when the activated / T cells had
been exposed to ES-62 (Figure 5C). DC maturation is
required for these conditioning effects on / T cells, as
such immunomodulation did not occur with immature
DCs. Also, while the results did not reach significance,
the observed effects were associated with increased
generation of IL-27, a cytokine that antagonizes IL-17
production (21,22), in the cocultures containing ES-62–
treated / T cells (data not shown).
ES-62–mediated modulation of / T cell re-
sponses also appears to occur during CIA in vivo. Thus,
such draining LN / T cells not only displayed reduced
expression of CD44 when analyzed ex vivo (Figure 5B),
but in situ analysis also demonstrated that / T cells in
ES-62–treated mice exhibited altered localization within
draining LNs, showing reduced distribution in the B cell
follicles compared to those from PBS-treated animals
with CIA (Figure 5D).
Reduction in the levels of IL-17–positive cells in
the joints of mice with CIA treated with ES-62. Consis-
tent with a pathogenic effector role of IL-17 in the joint,
in situ analysis showed that, while little or no IL-17
expression was detected in joints from naive mice (Fig-
ure 6A), there was strong expression of this cytokine in
joints from 2 representative PBS-treated mice with CIA
(articular scores 7 and 8). In contrast, IL-17 expression
was dramatically reduced in the joints of 2 representa-
tive ES-62–treated mice (articular scores 3 and 0).
Furthermore, examination of the cells producing IL-17
indicated that these cells consisted of both cells infiltrat-
ing the joint (Figures 6B and C), including large num-
bers of lymphocytes as indicated by size and morphology
(Figure 6C), and cells in the bone, such as multinucle-
ated osteoclasts (Figure 6B). IL-17 levels appeared to be
Figure 5. ES-62 modulates cross-talk between / T cells and dendritic cells (DCs) in vitro. A, IL-17 release (left) and CD44 expression (right) in
/ T cells from BALB/c mice. The / T cells were activated in vitro with recombinant IL-1 (rIL-1) plus rIL-23, with or without ES-62 (2 g/ml).
IL-17 release and CD44 expression were analyzed at 24 hours. CD44 expression is shown for resting cells (gray area), cells activated with rIL-1 plus
rIL-23 (thin line), and cells activated with rIL-1, rIL-23, and ES-62 (thick line). Values in the left panel are the mean  SD (n  3 samples per
group). B, Percentage of / T cells expressing CD44 in draining LNs from mice with CIA treated with PBS or ES-62. C, IL-17 levels, and IL-17
and RORt mRNA levels relative to GAPDH, in resting, activated (act), or ES-62–exposed activated / T cells cocultured with lipopolysaccharide-
activated DCs at the indicated ratios. IL-17 levels were determined at 24 hours. Values in the left panel are the mean  SD of triplicate samples
from a single experiment. Values in the middle panel are the mean  SEM pooled results of 4 independent experiments, normalized to values in
control activated / T cells. Values in the right panels (mRNA levels) are the mean SD (n 3 from a single representative experiment). D, Laser
scanning cytometry of B220 cells (black) and percent of / TCR cells (gray) within B cell follicles from mice with CIA, gated as described in
Materials and Methods. The first 4 panels show results for a representative PBS-treated mouse with CIA. In the last panel, squares represent the
mean of 2 sections from each mouse; horizontal lines represent the mean value for the treatment group (n  8 mice per group).   P  0.05;
  P  0.01;   P  0.001. See Figure 1 for other definitions.
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reduced at both sites in mice treated with ES-62 (Figure
6A). These data suggest that, as well as suppressing the
early IL-17–driven proinflammatory responses in the
draining LNs that are associated with the initiation of
pathogenesis, exposure to ES-62 in vivo reduces effector
IL-17 responses in the affected joints.
DISCUSSION
The recent proposal that IL-17 is a master regu-
lator of CIA pathogenesis suggested that targeting cel-
lular producers of this cytokine might provide a mecha-
nism for suppression of disease severity by ES-62 (2,3).
Consistent with this notion, the highly elevated levels
of IL-17 observed in the serum of mice with CIA,
compared to naive animals, were significantly reduced in
mice with CIA treated with ES-62 in the present study.
Furthermore, ES-62 reduced the percentage of IL-17
draining LN cells, relative to the control cohorts with
CIA, such that it was not significantly different from that
in naive DBA/1 mice. Although prophylactic treatment
with ES-62 on days 2, 0, and 21 resulted in an
50–60% reduction in the articular score, it is likely that
more frequent and/or higher doses of ES-62 would have
further reduced IL-17 responses and the resultant pa-
thology. Alternatively, since ES-62 typically reduces
IL-17 responses to levels near those observed in naive
DBA/1 mice, the residual pathology observed in the
presence of ES-62 could reflect IL-17–independent
pathogenic effector mechanisms.
It is certainly the case that CD4 and / T
cell–driven pathogenesis in CIA relies on the ability of
these cells to initiate IL-17–dependent responses
(14,23–25), although it has recently been suggested that
the induction of / T cells may be a result of CFA-
associated inflammation (14,23). However, we found
that the levels of IL-17 / T cells were not up-
regulated in mice immunized with CFA alone (results
not shown), indicating that IL-17 production by both
Figure 6. ES-62 suppresses the levels of IL-17–producing cells in the joints of mice with CIA. A, Joint sections from 2 representative naive mice,
2 representative mice with CIA treated with PBS (1 with an articular score of 7 and 1 with an articular score of 8), and 2 representative mice with
CIA treated with ES-62 (1 with an articular score of 3 and 1 with an articular score of 0). Red indicates IL-17; blue indicates nuclei. Isotype control
sections were IL-17 negative. B  bone; Ac  articular cavity; Sy  synovium; P  pannus. Original magnification 	 20. B and C, IL-17 cells in
the bone (B) and synovium (C) in the numbered sections from the mice with CIA treated with PBS in A (1–4). Original magnification 	 40. Arrow
indicates a multinucleated cell. Bars indicate relative magnification (bar in left panel of B 20 m [scan zoom	2.3]; bar in right panel of B 10 m
[scan zoom	2.1]; bar in left panel of C 5 m [scan zoom	2.5]; bar in right panel of C 20 m [scan zoom	2.6]). D, A model of the mechanism
of action of ES-62 modulating a complex network of dendritic cell (DC), CD4 T cell, and / T cell interactions to suppress pathogenic IL-17
responses in mice with CIA. TLR-2  Toll-like receptor 2; pAgR  phosphoantigen receptor (see Figure 1 for other definitions).
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CD4 and / T cells plays a role in the collagen
response and, importantly, that ES-62 targets both of
these major IL-17–producing compartments in the CIA
model used in this study.
DCs are a major target of ES-62 action in mod-
ulating the priming and polarization of Th cell responses
(16–18). Thus, we hypothesized that the reduction in the
numbers of Th17 cells reflected suppression of Th17 cell
priming by DCs. We subsequently found that in vitro
conditioning of BMDCs with ES-62 significantly inhib-
ited LPS-driven production of the cytokines TNF, IL-6,
and IL-23, the latter two of which are implicated in the
development and maintenance of the Th17 phenotype,
and a reduction in OVA-specific priming of IL-17
production by naive CD4 Th cells.
However, we also observed that ES-62 modulated
Th17 responses directly. Although naive CD4 T cells
do not express TLR-4, which is the receptor required
for ES-62 to mediate its antiinflammatory effects in
antigen-presenting cells (19,26), we observed up-
regulation of TLR-4 and MyD88 in parallel with up-
regulation of the signature transcription factor, RORt,
during in vitro polarization to the Th17 phenotype.
ES-62–mediated suppression of the resultant IL-17 re-
sponse therefore likely reflects not only the fact that
TLRs can be expressed by most T cell subsets, but also
the fact that TLR agonists (e.g., for TLR-3, -5, -7, and
-9) can modulate Teff or Treg cell responses in the
absence of antigen-presenting cells (for review, see ref.
27) and LPS/TLR-4 signaling can both induce and
enhance IL-23–stimulated IL-17 release from Th17 cells
differentiated in vitro (28).
We have found that ES-62 suppresses IL-17
release from Th17 cells differentiated in vitro in re-
sponse to IL-1 but not in response to IL-23 (Pineda MA,
et al: unpublished observations), a cytokine that has
been shown to commit naive T cells to a Th17 phenotype
via STAT-3 activation independently of MyD88 recruit-
ment (29). Therefore, ES-62 subversion of signaling via
TLR-4, with consequent down-regulation of MyD88, a
key signal transducer of the TLR/IL-1 receptor (IL-1R)
family (30), would provide a molecular rationale for the
observed decrease in Th17 polarization, given that it has
recently been reported (31,32) that IL-1R–associated
kinase 4 (IRAK-4) and IRAK-1, the downstream effec-
tors of IL-1R/MyD88 signaling, are required for such
polarization.
In contrast, ES-62 did not directly down-regulate
IL-17 production by / T cells in response to activation
with IL-1/IL-23. Consistent with this finding, we were
unable to detect TLR-4 expression by / T cells,
supporting the notion that modulation of / T cell
responses by LPS requires cooperation with DCs (33).
It was surprising, therefore, that we found that ES-62
suppressed the up-regulation of CD44 resulting from the
activation of / T cells in response to IL-1/IL-23. These
data suggested that ES-62 might directly modulate /
T cell activation, but not cytokine production, through
some undefined receptors, such as those involved in
the recognition of small phosphorylated molecules pres-
ent in mycobacteria that lead to DC activation by /
T cells (34,35), in a TLR-independent manner (36–39).
In turn, mature DCs can stimulate / T cells to promote
sustained immune responses (37,40), and, perhaps of
relevance to this study, DCs have been shown to mod-
ulate IL-17 production by / T cells (41). Thus, since
the active phosphorylcholine moiety of ES-62 (3) is
structurally reminiscent of the phosphorylated myco-
bacterial molecules, this suggested that ES-62 was pos-
sibly targeting / T cells via such receptors to modulate
bidirectional interaction with DCs, a hypothesis sup-
ported by the fact that ES-62 down-regulated the pro-
duction of IL-17 and tended to up-regulate the produc-
tion of IL-27, a cytokine that suppresses CIA (22,42,43),
in DC–/ cocultures.
The targeting of CD44 expression by / T cells
that was observed both in vitro and in vivo in the pres-
ent study may be physiologically relevant to ES-62–
mediated protection against CIA, since such modulation
would impact lymphocyte migration during CIA (44),
particularly to the joint (45). Indeed, in situ laser scan-
ning cytometry revealed that exposure to ES-62 in vivo
modulates the localization of / T cells within the
draining LNs of mice with CIA, and this may, in turn,
modulate bidirectional signaling between / T cells and
DCs to subvert initiation of the inflammatory phenotype
driving autoimmunity. Moreover, and perhaps reflecting
suppression of the CD44-mediated migration of IL-17–
producing lymphocytes to the site of inflammation, we
have also shown that ES-62 dramatically reduces the
levels of IL-17 infiltrating cells in the joints. This is
likely to be of importance therapeutically, since IL-17
produced during the initiator phase induces the recruit-
ment and accumulation of inflammatory cells, particu-
larly neutrophils, to the joints and the release of pro-
inflammatory chemokines, cytokines, and matrix
metalloproteinases (7,8,46), which ultimately results in
osteoclastogenesis and bone destruction in situ (47).
Interestingly, our data suggest that during the
effector phase, infiltrating cells and bone cells could
both be producing IL-17 in situ, since some of the
IL-17 cells in the bone appeared multinucleated (Fig-
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ure 6B), suggesting that they could be osteoclasts. More-
over, the infiltrating cells in the joints of mice with CIA
contained large numbers of small IL-17 mononuclear
cells that appeared to be lymphocytes, consistent with
ES-62 blocking the migration of pathogenic effector
Th17 and/or IL-17–producing / T cells to the site of
inflammation. Importantly, levels of all classes of IL-17–
producing cells in the joint appeared to be reduced in
the ES-62–treated mice.
Taken together, these data suggest that ES-62
targets the IL-17 inflammatory axis at several regulatory
points in order to optimize safe modulation of patho-
genic IL-17 responses (Figure 6D). Thus, it targets
cells of the innate immune system (DCs and / T cells)
to inhibit initiation of pathogenic responses and also,
by acting directly on Th17 cells, to suppress ongoing
adaptive responses. Mechanistically, given the increasing
evidence of TLR signaling in the initiation (DC) and
amplification of Th17 cell– and / T cell–mediated
IL-17 responses and autoimmune inflammation (28,31,48),
it is pertinent that ES-62 rewires TLR-2–, TLR-4–, and
TLR-9–driven maturation of DCs to an antiinflam-
matory phenotype in a TLR-4–dependent manner (19).
This was reflected in the present study by the inhibition
of LPS-induced TNF, IL-6, and IL-23 production, as
well as by the release of increased levels of IL-27,
resulting in the suppression of differentiation and/or
maintenance of the Th17 phenotype.
ES-62 can also act directly on CD4 T cells to
suppress IL-1–dependent Th17 differentiation, and this
likely involves TLR-4–mediated down-regulation of
MyD88, leading to uncoupling of IL-1R from IRAK-1/4
signals that are essential for Th17 polarization (31,32).
Since MyD88 is a key signal transducer for all TLR
family members except for TLR-3 (interestingly, sig-
naling of which is not modulated by ES-62 [19]), the
recent finding that Th17 responses and consequent
autoimmune pathogenesis are promoted by TLR-2 sig-
naling in vivo (28) suggests that ES-62 may down-
regulate MyD88 expression as a general mechanism of
targeting aberrant Th17 responses and inflammatory
disease.
Interestingly, ES-62 also acts directly on / T
cells, possibly via phosphoantigen receptors, not only to
modulate the bidirectional DC–/ cell interactions re-
quired to drive subsequent adaptive Th17 responses, but
also to down-regulate CD44 expression and suppress
migration of such pathogenic cells to the joint. Certainly,
it dramatically suppresses pathogenic IL-17 production
by effector cells within the joint.
Hence, the use of ES-62 to modulate this highly
inflammatory mediator by targeting both DC matura-
tion and Teff cell responses through subversion of
TLR-4 signaling, without compromising the host im-
mune response to infection (26), constitutes a highly
appealing therapeutic strategy for RA.
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